CN113057967A - Stem cell composition for treating diabetes and preparation and application thereof - Google Patents
Stem cell composition for treating diabetes and preparation and application thereof Download PDFInfo
- Publication number
- CN113057967A CN113057967A CN201911296023.0A CN201911296023A CN113057967A CN 113057967 A CN113057967 A CN 113057967A CN 201911296023 A CN201911296023 A CN 201911296023A CN 113057967 A CN113057967 A CN 113057967A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- preparation
- dencichine
- peripheral blood
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 36
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 21
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 21
- 239000011886 peripheral blood Substances 0.000 claims abstract description 21
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- NEEQFPMRODQIKX-REOHCLBHSA-N N(3)-oxalyl-L-2,3-diaminopropionic acid Chemical compound OC(=O)[C@@H](N)CNC(=O)C(O)=O NEEQFPMRODQIKX-REOHCLBHSA-N 0.000 claims abstract description 20
- 235000007242 delphinidin Nutrition 0.000 claims abstract description 20
- -1 delphinidin glucoside Chemical class 0.000 claims abstract description 20
- 229930182478 glucoside Natural products 0.000 claims abstract description 20
- 239000004471 Glycine Substances 0.000 claims abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract description 11
- 230000000225 effect on diabetes Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 239000008103 glucose Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 229940082372 glycine 3 mg/ml Drugs 0.000 description 1
- 229940068388 glycine 5 mg/ml Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a stem cell composition for treating diabetes, which comprises the following components of human peripheral blood mesenchymal stem cells, glycine, dencichine and delphinidin glucoside in proportion: (104‑106A plurality of): (100-500 mg): (50-200 mg): (10-50 mg). The invention also provides a stem cell preparation prepared by the stem cell composition and application thereof. The stem cell composition provided by the invention has better treatment effect on diabetes by adopting the matching of human peripheral blood mesenchymal stem cells and glycine, dencichine and delphinidin glucoside, can effectively control the blood sugar level, does not contain any toxic or side components, and is safe and effective.
Description
Technical Field
The invention relates to the field of biological medicines, in particular to a stem cell composition for treating diabetes, and a preparation and application thereof.
Background
Diabetes is one of the most common epidemic diseases worldwide, and the mortality rate of diabetes is second to vascular diseases and malignant tumors in developed countries and becomes the third leading cause of diseases. It is a chronic systemic disease related to genetic factors and various environmental factors, and is a syndrome of carbohydrate and fat metabolism disorder of the body caused by insufficient insulin secretion or utilization, and diabetic liver disease becomes another chronic complication which is increasingly emphasized by people besides kidney, heart, retina and neuropathy in chronic complications of diabetes. The number of diabetes patients in China is on a very obvious rising trend in recent years, and the main type of diabetes patients is type 2 diabetes patients, which becomes one of the problems mainly threatening the life health of people in China.
Although a large number of hypoglycemic drugs are clinically applied, the side effects are large, the use is inconvenient, and the curative effect is unstable. In recent years, mesenchymal stem cell transplantation therapy has become a hot spot of clinical research, provides new hope for clinical treatment of diabetes, and obtains primary curative effect, but the effect still needs to be improved.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provide a stem cell composition for treating diabetes, a preparation and an application thereof.
The first aspect of the invention is a stem cell composition for treating diabetes, which comprises the components of human peripheral blood mesenchymal stem cells, glycine, dencichine and delphinidin glucoside.
Wherein the stem cell composition comprises human peripheral blood mesenchymal stem cells, glycine, dencichine and delphinidin glucoside in the following proportions: (104-106A plurality of): (100-500 mg): (50-200 mg): (10-50 mg).
In a second aspect of the present invention, there is provided a stem cell preparation for treating diabetes, wherein the active ingredient is the stem cell composition according to the first aspect of the present invention.
Preferably, the stem cell preparation comprises a first agent prepared by suspending the human peripheral blood mesenchymal stem cells in normal saline and a second agent prepared by dissolving glycine, dencichine and delphinidin glucoside in normal saline.
Wherein the density of the human peripheral blood mesenchymal stem cells in the first dose is 104-106Per ml, e.g. 1042X 10 pieces/ml44X 10 pieces/ml46X 10 pieces/ml48 × 10 pieces/ml4Each/ml, 1052X 10 pieces/ml54X 10 pieces/ml56X 10 pieces/ml58 × 10 pieces/ml5Each/ml, 106Pieces/ml, etc. Preferably, the density of the human peripheral blood mesenchymal stem cells is (1-6). times.105One per ml.
Wherein the concentration of glycine in the second agent is 1-5mg/ml, such as 1mg/ml, 1.5mg/ml, 2mg/ml, 2.5mg/ml, 3mg/ml, 3.5mg/ml, 4mg/ml, 4.5mg/ml, 5mg/ml and the like. Preferably, the concentration of glycine is 3 mg/ml.
Wherein the concentration of dencichine in the second agent is 0.5-2mg/ml, such as 0.5mg/ml, 0.8mg/ml, 1mg/ml, 1.2mg/ml, 1.4mg/ml, 1.5mg/ml, 1.6mg/ml, 1.8mg/ml, 2mg/ml, etc. The concentration of the dencichine is 1 mg/ml.
Wherein the delphinidin glucoside concentration in the second preparation is 0.1-0.5mg/ml, such as 0.1mg/ml, 0.2mg/ml, 0.25mg/ml, 0.3mg/ml, 0.35mg/ml, 0.4mg/ml, 0.45mg/ml, 0.5mg/ml, etc. Preferably, the concentration of delphinidin glucoside is 0.3 mg/ml.
A third aspect of the invention provides the use of a stem cell composition according to the first aspect of the invention, or a stem cell preparation according to the second aspect of the invention, in the manufacture of a medicament for the treatment of diabetes.
The invention has the beneficial effects that:
the stem cell composition provided by the invention has better treatment effect on diabetes by adopting the matching of human peripheral blood mesenchymal stem cells and glycine, dencichine and delphinidin glucoside, can effectively control the blood sugar level, does not contain any toxic or side components, and is safe and effective.
Detailed Description
The present invention will be better understood by reference to the following examples. The materials and instruments adopted by the invention are all common commercial products and can be purchased in the market.
Example 1
Collecting peripheral blood, and separating plasma and peripheral blood mononuclear cells; resuspending peripheral blood mononuclear cells with an M199 culture medium containing the plasma, and adding EGF factors for 3-5 days; removing nonadherent suspension cells, and replacing the M199 culture medium added with the plasma and the EGF factors to continue culture; when the cells reach 80% -90% fusion, digesting the cells to obtain the cultured peripheral blood mesenchymal stem cells.
Example 2
A stem cell preparation for treating diabetes, comprising a first dose prepared by suspending the human peripheral blood mesenchymal stem cells prepared in example 1 in a normal saline and a second dose prepared by dissolving glycine, dencichine and delphinidin glucoside in a normal saline.
The density of the human peripheral blood mesenchymal stem cells in the first dose is 105Per ml; the second preparation contains glycine 3mg/ml, dencichine 1mg/ml, and delphinidin glucoside 0.3 mg/ml.
Example 3
A stem cell preparation for treating diabetes, comprising a first dose prepared by suspending the human peripheral blood mesenchymal stem cells prepared in example 1 in a normal saline and a second dose prepared by dissolving glycine, dencichine and delphinidin glucoside in a normal saline.
The density of the human peripheral blood mesenchymal stem cells in the first dose is 104Per ml; the second preparation contains glycine 5mg/ml, dencichine 0.5mg/ml, and delphinidin glucoside 0.1 mg/ml.
Example 4
A stem cell preparation for treating diabetes, comprising a first dose prepared by suspending the human peripheral blood mesenchymal stem cells prepared in example 1 in a normal saline and a second dose prepared by dissolving glycine, dencichine and delphinidin glucoside in a normal saline.
The density of the human peripheral blood mesenchymal stem cells in the first dose is 106Per ml; the second preparation contains 1mg/ml of glycine, 2mg/ml of dencichine, and 0.5mg/ml of delphinidin glucoside.
Comparative example 1
This comparative example differs from example 2 in that the second agent does not contain glycine.
Comparative example 2
This comparative example differs from example 2 in that no dencichine is included in the second dose.
Comparative example 3
This comparative example differs from example 2 in that the second agent does not contain delphinidin glucoside.
Comparative example 4
This comparative example differs from example 2 in that the first agent was not included.
Test 1 animal test
(1) Animal feeding
Male Wistar rats of clean grade, weighing 200-220 g.
All rats are raised in the same room and in different cages, are naturally illuminated, are fed freely and are fed with water, the raising temperature is 18-25 ℃, the relative humidity is 40-50%, and high decibel noise is avoided; ensuring good ventilation for 1 h/time and 3 times/d; the bedding is changed frequently for 2-3 times per week. The experiment is started after the breeding for one week is adapted to the test environment. And (5) fasting for 12 hours before molding without water supply.
(2) Preparation of diabetes model
After the rats are adaptively raised for 7 days, the rats are fasted and are not forbidden to be watered for 12 hours, a single intraperitoneal injection is carried out on STZ40mg/kg (0.01mol/L, pH4.2) for 1 time/d for 5 days continuously, and control animals are intraperitoneally injected with equal volume of 0.1mol/L citrate buffer solution for 1 time/d for 5 days continuously. Within 1 week after the last injection, blood glucose was measured with a blood glucose meter and urine glucose was measured with urine glucose test paper. Diabetic rats were treated with continuous 3 days with blood glucose >16.7mmol/L and drug experiments were performed on day 4.
(3) Animals were randomized into groups and observed for intervention therapy
Setting a normal group, 10 normal rats, carrying out no treatment, carrying out normal diet, randomly dividing animals after successful molding into 8 groups, and respectively administering the following reagents into 10 groups:
1. stem cell preparation of example 2;
2. stem cell preparation of example 3;
3. the stem cell preparation of example 4;
4. normal diet (modeling) without any treatment;
5. the stem cell preparation of comparative example 1;
6. the stem cell preparation of comparative example 2;
7. the stem cell preparation of comparative example 3;
8. compound solvent in comparative example 4.
Respectively administering the medicine to rats of each group every day, performing intragastric administration on a second dose, and after 30min, performing tail vein injection on the first dose, wherein the administration dose is 1ml/kg body weight of the first dose, the administration dose is 100ml/kg body weight of the second dose (only the second dose is administered to the group of comparative example 4), and measuring the blood sugar value of the rats of each group at nine am every week; general conditions of rats were monitored and specimens were collected, fixed and cryopreserved.
(4) Glucose tolerance test
At the end of 6 weeks of the experiment, after fasting for 6 hours, the rats were gavaged with 1ml/100g (equivalent to 2 g/kg) of 20% glucose, and the fasting (0min) and 30, 60 and 120min blood glucose levels after taking the glucose were measured using a model JPS-3+ glucometer, supplied by Beijing Yicheng science and technology company, respectively, and the results are shown in Table 1 below.
TABLE 1 blood glucose values (mmol. L) of various groups of animals at different time points-1)
| 0min | 30min | 60min | 120min | |
| Normal group | 6.40 | 7.95 | 7.30 | 6.58 |
| Example 2 | 19.21 | 20.01 | 17.17 | 13.98 |
| Example 3 | 19.88 | 20.46 | 17.98 | 14.23 |
| Example 4 | 20.45 | 21.02 | 18.66 | 14.57 |
| Molding set | 21.70 | 33.01 | 25.12 | 25.43 |
| Comparative example 1 | 20.91 | 25.43 | 21.03 | 20.17 |
| Comparative example 2 | 21.43 | 26.51 | 22.41 | 19.85 |
| Comparative example 3 | 21.08 | 26.11 | 23.03 | 19.22 |
| Comparative example 4 | 21.97 | 30.48 | 24.66 | 23.58 |
As can be seen from the results in Table 1, the rats in the blank control group had normal glucose-regulating ability. The blood sugar of the rats in the diabetic group is always at a high level 30-60min after the administration of glucose, and slightly decreases by 120min, which shows that the glucose tolerance of the rats with diabetes is obviously reduced and the glucose regulation function is damaged. In the administration group, blood sugar concentration at 60min and 120min is obviously lower than that of the diabetes group at the corresponding time point, and particularly, blood sugar value is obviously reduced compared with that of the diabetes group at 120min, which indicates that the sugar regulation function of the administration group is damaged and slowed down.
The embodiments of the present invention have been described in detail, but the embodiments are merely examples, and the present invention is not limited to the embodiments described above. Any equivalent modifications and substitutions to those skilled in the art are also within the scope of the present invention. Accordingly, equivalent changes and modifications made without departing from the spirit and scope of the present invention should be covered by the present invention.
Claims (10)
1. A stem cell composition for treating diabetes is characterized in that the components of the stem cell composition comprise human peripheral blood mesenchymal stem cells, glycine, dencichine and delphinidin glucoside.
2. The stem cell composition of claim 1, wherein the ratio of the human peripheral blood mesenchymal stem cells, glycine, dencichine, delphinidin glucoside is: (104-106A plurality of): (100-500 mg): (50-200 mg): (10-50 mg).
3. A stem cell preparation for treating diabetes mellitus, which comprises the stem cell composition according to claim 1 or 2 as an active ingredient.
4. The stem cell preparation according to claim 3, comprising a first preparation prepared by suspending the human peripheral blood mesenchymal stem cells in a normal saline solution and a second preparation prepared by dissolving glycine, dencichine and delphinidin glucoside in a normal saline solution.
5. The stem cell preparation of claim 4, wherein the density of human peripheral blood mesenchymal stem cells in the first dose is 104-106Per ml; the second preparation contains glycine 1-5mg/ml, dencichine 0.5-2mg/ml, and delphinidin glucoside 0.1-0.5 mg/ml.
6. The stem cell preparation of claim 5, wherein the density of the human peripheral blood mesenchymal stem cells is (1-6) x 105One per ml.
7. The stem cell preparation of claim 5, wherein the glycine is at a concentration of 3 mg/ml.
8. The stem cell preparation of claim 5, wherein the concentration of dencichine is 1 mg/ml.
9. The stem cell preparation of claim 5, wherein the delphinidin glucoside is at a concentration of 0.3 mg/ml.
10. Use of a stem cell composition according to claim 1 or 2, or a stem cell preparation according to any one of claims 3 to 9, in the manufacture of a medicament for the treatment of diabetes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911296023.0A CN113057967A (en) | 2019-12-16 | 2019-12-16 | Stem cell composition for treating diabetes and preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911296023.0A CN113057967A (en) | 2019-12-16 | 2019-12-16 | Stem cell composition for treating diabetes and preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113057967A true CN113057967A (en) | 2021-07-02 |
Family
ID=76557888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911296023.0A Pending CN113057967A (en) | 2019-12-16 | 2019-12-16 | Stem cell composition for treating diabetes and preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113057967A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453199A (en) * | 2018-11-05 | 2019-03-12 | 北京世纪劲得生物技术有限公司 | The application of mescenchymal stem cell, composition and injection in preparation treatment diabetes medicament |
| CN111484953A (en) * | 2019-01-28 | 2020-08-04 | 福建省农业科学院农业生物资源研究所 | Bacillus capable of promoting growth and dissolving phosphorus and application thereof |
-
2019
- 2019-12-16 CN CN201911296023.0A patent/CN113057967A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453199A (en) * | 2018-11-05 | 2019-03-12 | 北京世纪劲得生物技术有限公司 | The application of mescenchymal stem cell, composition and injection in preparation treatment diabetes medicament |
| CN111484953A (en) * | 2019-01-28 | 2020-08-04 | 福建省农业科学院农业生物资源研究所 | Bacillus capable of promoting growth and dissolving phosphorus and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| LI, YUE-YING 等: "Adipose-derived mesenchymal stem cells ameliorate STZ-induced pancreas damage in type 1 diabetes", 《BIO-MEDICAL MATERIALS AND ENGINEERING》 * |
| PON VELAYUTHAM ANANDHBABU 等: "Recent advances in understanding the anti-diabetic actions of dietary flavonoids", 《THE JOURNAL OF NUTRITIONAL BIOCHEMISTRY》 * |
| 张希 等: "三七素的药理作用研究进展", 《现代药物与临床》 * |
| 李科学: "甘氨酸对STZ诱导的I型糖尿病的保护作用及其机制研究", 《中国病理生理杂志》 * |
| 杨涛 等: "内分泌代谢性疾病的生物治疗", 《基因诊断与细胞治疗》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN101584704B (en) | Medicinal application of medicinal salt or derivative of heparin and low molecular heparin | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN113057967A (en) | Stem cell composition for treating diabetes and preparation and application thereof | |
| CN111304134A (en) | Lactobacillus plantarum capable of effectively relieving diabetes | |
| CN113876786B (en) | Liver fibrosis prevention and treatment medicine | |
| US20180030102A1 (en) | Application of metrnl protein in preparing hypolipidemic, hypoglycemic medicine | |
| CN107158026A (en) | Application of the low-ester pectin in preventing and treating or auxiliary treatment diabetes | |
| CN1368979A (en) | Hematopoietic arabinogalactan composition | |
| CN106562985A (en) | Medicinal health care applications of linarin | |
| CN101032552A (en) | Curing purpose of total flavonoids from mulberry tree leaf | |
| CN101491518B (en) | Combination for treating tumor | |
| CN107802629B (en) | A kind of purposes of pharmaceutical composition in treatment of atherosclerosis drug is prepared | |
| JP2002000229A (en) | Health food | |
| CN113244208B (en) | Application of HPA in preparation of medicine for treating non-alcoholic fatty liver disease | |
| CN112870212B (en) | Application of Anoectochilus roxburghii glycoside in preparation of medicine for preventing and/or treating pulmonary fibrosis | |
| CN113995833B (en) | Adenosine deaminase and application of modification thereof in preparation of diabetes wound repair drugs | |
| CN114099493B (en) | Active compound for inhibiting insulin resistance and application thereof | |
| TWI364286B (en) | Compositions for diabetes treatment and prophylaxis | |
| RU2126260C1 (en) | Cell suspension-based immunocorrecting drug and using this drug in a method of treating diabetes mellitus | |
| CN102475712B (en) | Pharmaceutical composition used for preventing and treating diabetes and complications thereof | |
| CN114404568B (en) | Sericin polypeptide injection preparation and application thereof | |
| CN110746487B (en) | Short peptides and use of compositions thereof for treating/preventing diabetes and related diseases | |
| CN107998142B (en) | A kind of combination of oral medication for treating myocardial ischemia-reperfusion injury | |
| CN116036106A (en) | Application of medicine for treating lymphedema |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210702 |